AU618085B2 - Occlusive body for administering a physiologically active substance - Google Patents

Occlusive body for administering a physiologically active substance Download PDF

Info

Publication number
AU618085B2
AU618085B2 AU32895/89A AU3289589A AU618085B2 AU 618085 B2 AU618085 B2 AU 618085B2 AU 32895/89 A AU32895/89 A AU 32895/89A AU 3289589 A AU3289589 A AU 3289589A AU 618085 B2 AU618085 B2 AU 618085B2
Authority
AU
Australia
Prior art keywords
membrane
active substance
physiologically active
cavity
occlusive body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32895/89A
Other languages
English (en)
Other versions
AU3289589A (en
Inventor
John Mark Tucker
Mark Rupert Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3289589A publication Critical patent/AU3289589A/en
Application granted granted Critical
Publication of AU618085B2 publication Critical patent/AU618085B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU32895/89A 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance Ceased AU618085B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound
GB8804164 1988-02-23

Publications (2)

Publication Number Publication Date
AU3289589A AU3289589A (en) 1989-09-22
AU618085B2 true AU618085B2 (en) 1991-12-12

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32895/89A Ceased AU618085B2 (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Country Status (11)

Country Link
US (1) US5254346A (cg-RX-API-DMAC7.html)
EP (2) EP0336543A1 (cg-RX-API-DMAC7.html)
JP (1) JP2716231B2 (cg-RX-API-DMAC7.html)
KR (1) KR970009723B1 (cg-RX-API-DMAC7.html)
AU (1) AU618085B2 (cg-RX-API-DMAC7.html)
DE (1) DE68915291T2 (cg-RX-API-DMAC7.html)
ES (1) ES2052071T3 (cg-RX-API-DMAC7.html)
GB (1) GB8804164D0 (cg-RX-API-DMAC7.html)
IN (1) IN172748B (cg-RX-API-DMAC7.html)
WO (1) WO1989007959A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA891403B (cg-RX-API-DMAC7.html)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
EP0470007B1 (en) * 1990-08-03 1995-03-15 Terumo Kabushiki Kaisha Wound-covering materials
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE4236886C2 (de) * 1992-10-31 1997-11-20 Klocke Verpackungs Service Behälter zur Aufnahme von aromatischen Substanzen
DE69333009T2 (de) * 1992-11-09 2003-12-04 Neurogesx, Inc. Transdermale verabreichung von ketorolac
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
MX9603667A (es) * 1994-03-07 1997-06-28 Theratech Inc Dispositivo de suministro transdermico compuesto adhesivo que contiene droga.
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
JP4116447B2 (ja) 2001-05-01 2008-07-09 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス ヒドロゲル組成物
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
RU2286801C2 (ru) 2001-05-01 2006-11-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Двухфазные биоадгезионные композиции, абсорбирующие воду
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1546184A4 (en) * 2002-07-16 2006-08-23 Univ South Florida HUMAN IMMUNOSUPPRESSIVE PROTEIN
EP2316459B1 (en) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2729967C (en) * 2002-12-13 2018-01-16 Schering-Plough Healthcare Products, Inc. Use of a transdermal or transmucosal ingredient delivery device
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
WO2004093788A2 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
WO2005007020A2 (en) 2003-07-03 2005-01-27 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
JP4604034B2 (ja) * 2003-09-08 2010-12-22 マクニール・アクチェボラーグ ニコチン製剤およびその使用
EP1713450B1 (en) 2004-01-30 2021-10-06 Corium, Inc. Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
EP1747022A4 (en) 2004-04-23 2010-03-31 Univ Columbia INHIBITION OF HAIRLESS PROTEIN MRNA
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
JP5270158B2 (ja) 2004-08-05 2013-08-21 コリウム インターナショナル， インコーポレイテッド 粘着性組成物
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
CN101146523B (zh) 2004-10-21 2010-12-29 杜雷科特公司 透皮给药系统
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1965776A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
US20090246264A1 (en) * 2005-12-08 2009-10-01 Fertin Pharma Transdermal Tobacco Alkaloid Patch
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US9109204B2 (en) 2006-02-28 2015-08-18 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
EP2054031B1 (en) 2006-07-21 2016-04-06 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2078026B1 (en) 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
CN101790373A (zh) * 2007-05-31 2010-07-28 费廷药业股份有限公司 烟草生物碱储库型经皮贴剂
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
MX2010001242A (es) 2007-07-30 2010-07-02 Alltranz Inc Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
CA2734877C (en) 2008-08-22 2014-04-29 Sanofi-Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
SG172885A1 (en) 2009-01-23 2011-08-29 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
ES2540232T3 (es) 2009-07-08 2015-07-09 Dermira (Canada), Inc. Análogos de TOFA útiles en el tratamiento de trastornos o afecciones dermatológicas
US20110034415A1 (en) * 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
US20110038904A1 (en) * 2009-08-17 2011-02-17 Silipos Inc. Gel Product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
EP2519520A1 (en) 2009-12-23 2012-11-07 Sanofi [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(1h-pyrrolopyridinyl)-methanone derivatives as tryptase inhibitors
EP2516418B1 (en) 2009-12-23 2014-05-14 Sanofi Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20110288093A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
WO2011133596A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
JP5266430B2 (ja) 2010-04-24 2013-08-21 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
RU2672100C2 (ru) 2010-07-28 2018-11-12 Райджел Фармасьютикалз, Инк. Композиции и способы ингибирования пути jak
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR102027394B1 (ko) 2010-11-02 2019-10-01 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
BR112013011830B1 (pt) 2010-11-13 2022-03-15 Innocrin Pharmaceuticals, Inc Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
CA2820718A1 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR112013015572A2 (pt) 2010-12-20 2016-09-27 Colgate Palmolive Co composição para cuidado oral de gelatina encapsulada contendo hidrofílico ativo, agente de estruturação hidrofóbico e transportador de óleo
EP2678297A2 (en) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin analogs that inhibit ftsz protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
EA201490038A1 (ru) 2011-06-19 2014-04-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2012273103B2 (en) 2011-06-19 2017-04-20 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
AU2012273004B2 (en) 2011-06-23 2017-04-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
KR102070345B1 (ko) 2011-12-11 2020-01-28 마이코비아 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CN104136427B (zh) 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
EP2828241B1 (en) 2012-03-23 2018-09-12 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
SI2830662T1 (sl) 2012-03-29 2019-01-31 The Trustees Of Columbia University In The City Of New York Postopki zdravljenja motenj izgube las
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2948150A1 (en) 2013-01-25 2015-12-02 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
US20150157509A1 (en) * 2013-12-11 2015-06-11 Oscar Polk Atkinson Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
JP6625071B2 (ja) 2014-03-07 2019-12-25 ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性ｃｒｍｐ２ペプチド
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
PL3271347T3 (pl) 2015-03-19 2022-11-21 Mycovia Pharmaceuticals, Inc. Związki przeciwgrzybicze i sposoby wytwarzania
EP3719016A1 (en) 2015-08-04 2020-10-07 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
KR102798709B1 (ko) 2015-09-18 2025-04-23 마이코비아 파마슈티컬즈, 인코포레이티드 항진균 화합물 제조 방법
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EP3397629B1 (en) 2015-12-30 2023-04-19 NQP 1598, Ltd. Metalloenzyme inhibitor compounds
CN109071750B (zh) 2016-03-08 2022-08-02 生活实验公司 持久化妆品组合物
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
US10981928B2 (en) 2016-06-29 2021-04-20 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
EP3532470B1 (en) 2016-10-26 2022-12-07 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
EP4212523A1 (en) 2016-10-26 2023-07-19 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CN120987917A (zh) 2016-12-29 2025-11-21 箕星药业香港有限公司 金属酶抑制剂化合物
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
JP7167069B2 (ja) 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
BR112020004127A2 (pt) 2017-09-13 2020-09-01 Living Proof, Inc. composições protetoras de cor
EP3681920B1 (en) 2017-09-13 2025-06-25 Living Proof, Inc. Long lasting cosmetic compositions
CN111356501A (zh) 2017-11-20 2020-06-30 生活实验公司 实现持久化妆品性能的属性
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
BR112020021902B1 (pt) 2018-04-27 2024-02-20 Living Proof, Inc Composições cosméticas de poliuretano-ureia para tratamento capilar, método de preservação da ondulação no cabelo humano e os usos de poliuretano-ureia
BR112020022420A2 (pt) 2018-05-03 2021-03-02 Rigel Pharmaceuticals, Inc. composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para produzir o composto
DK3788045T3 (da) 2018-05-03 2023-06-26 Rigel Pharmaceuticals Inc RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CA3126224A1 (en) 2019-01-08 2020-07-16 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
JP7681570B2 (ja) 2019-08-14 2025-05-22 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群をブロック又は改善する方法
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
MY198690A (en) 2019-09-06 2023-09-16 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
JP7376218B2 (ja) 2019-09-06 2023-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
KR102824962B1 (ko) 2019-11-07 2025-06-26 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 억제 화합물
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
US12459941B2 (en) 2022-03-31 2025-11-04 Rigel Pharmaceuticals, Inc. Tricyclic IRAK inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
EP0186019B1 (de) * 1984-12-22 1993-10-06 Schwarz Pharma Ag Wirkstoffpflaster
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Also Published As

Publication number Publication date
IN172748B (cg-RX-API-DMAC7.html) 1993-11-20
DE68915291D1 (de) 1994-06-16
US5254346A (en) 1993-10-19
DE68915291T2 (de) 1994-09-01
EP0336543A1 (en) 1989-10-11
KR970009723B1 (ko) 1997-06-17
JPH03503636A (ja) 1991-08-15
KR900700153A (ko) 1990-08-11
JP2716231B2 (ja) 1998-02-18
AU3289589A (en) 1989-09-22
EP0508979A1 (en) 1992-10-21
ZA891403B (en) 1989-11-29
EP0508979B1 (en) 1994-05-11
WO1989007959A1 (en) 1989-09-08
ES2052071T3 (es) 1994-07-01
GB8804164D0 (en) 1988-03-23

Similar Documents

Publication Publication Date Title
AU618085B2 (en) Occlusive body for administering a physiologically active substance
US4927687A (en) Sustained release transdermal drug delivery composition
US5273755A (en) Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US4687481A (en) Transdermal drug delivery system
US4624665A (en) Method of transdermal drug delivery
US4834978A (en) Method of transdermal drug delivery
JP4982670B2 (ja) ２種以上の活性物質のためのドラッグデリバリーシステム
CA1333689C (en) Transdermal drug delivery device
US5234690A (en) Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5614212A (en) Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6024975A (en) Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US4743249A (en) Dermal and transdermal patches having a discontinuous pattern adhesive layer
CA2229184C (en) Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US3797494A (en) Bandage for the administration of drug by controlled metering through microporous materials
US5788983A (en) Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
CA1302824C (en) Device for administering an active agent to the skin or mucosa
CA1270714A (en) Multicompartmentalized dermal and transdermal patches
US5273756A (en) Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US4810499A (en) Transdermal drug delivery system and method
FI100456B (fi) Gestodeenia sisältävän vaikuttavan aineen transdermaaliseen antoon tar koitetun välineen käyttö raskauden ehkäisyyn
JPH044295B2 (cg-RX-API-DMAC7.html)
US6074665A (en) Transdermal therapeutic system for administering active agents to the human body via the skin
EP0273004B1 (de) Benutzer-aktivierte Therapeutische Systeme
EP0252459A1 (en) Compartmentalized transdermal delivery system
JP2010531684A (ja) 密閉膜を用いる貯留槽システム